Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis-Reference-Cited by-同舟云学术

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Published:2022-06-07 Issue:7 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Ordaya Eloy E¹^ORCID,Beam Elena¹^ORCID,Yao Joseph D²^ORCID,Razonable Raymund R¹,Vergidis Paschalis¹^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Mayo Clinic , Rochester, Minnesota , USA

2. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, Minnesota , USA

Abstract

Abstract Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac283/43965565/ofac283.pdf

Reference26 articles.

1. Excess mortality in solid organ transplant recipients hospitalized with COVID-19: a large-scale comparison of SOT recipients hospitalized with or without COVID-19;Jering;Clin Transplant,2022

2. Case fatality rate of cancer patients with COVID-19 in a New York hospital system;Mehta;Cancer Discov,2020

3. COVID-19 in patients with lung cancer;Luo;Ann Oncol,2020

4. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study;Kates;Clin Infect Dis,2021

5. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies;Wang;Emerg Microbes Infect,2022

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients;Journal of Clinical Medicine;2024-03-31

2. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis;European Journal of Medical Research;2024-01-05

3. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak;Expert Review of Anti-infective Therapy;2023-10-24

4. Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study;Biomolecules;2023-08-22

5. Real-World Experience of Tixagevimab–cilgavimab in High-risk, Immunocompromised Coronavirus Disease 2019 Patients;Journal of Clinical Infectious Disease Society;2023-07